Biovail Tiazac Market Share Is Significant Enough To Be Reference Drug - FDA
Forest/Biovail's Tiazac extended-release diltiazem will be relisted in the Orange Book as a reference listed drug, allowing submission of ANDAs for the brand.
You may also be interested in...
Andrx is petitioning FDA to reconsider its denial of the firm's previous citizen's petition in an effort to prevent market entry of Biovail's generic version of Hoechst Marion Roussel's Cardizem CD after expiration of Andrx' exclusivity Dec. 19.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011